Chinese Journal of Pharmacovigilance ›› 2019, Vol. 16 ›› Issue (4): 246-247.
Previous Articles Next Articles
LI Wenling1, JIN Wei2, CHEN Bohua1, XU Beiming3,*
Received:2019-05-09
Revised:2019-05-09
Online:2019-04-20
Published:2019-05-09
CLC Number:
LI Wenling, JIN Wei, CHEN Bohua, XU Beiming. One Case of Cellulitis Induced by Pramipexole Hydrochloride Tablets[J]. Chinese Journal of Pharmacovigilance, 2019, 16(4): 246-247.
Add to citation manager EndNote|Ris|BibTeX
| [1] 中华医学会神经病学分会. 帕金森病及运动障碍学组中国帕金森病治疗指南 (第三版)[J]. 中华神经科杂志,2014,47(6):428-433. [2] 李珉,宋淦. 盐酸普拉克索速释片与多巴丝肼片治疗帕金森病的临床效果及安全性评价[J]. 中外医学研究,2018,16(8):28-30. [3] 何浩,杨文明,王晓,等. MicroRNA-7在帕金森病中的作用及研究进展[J]. 安徽医药,2018,22(4):599-602. [4] 杨晓鲲,徐明元,范云飞,等. 一种预测下肢蜂窝组织炎的新评分表[J]. 西南国防医药,2018,28(3):277-280. [5] 唐洁,刘智慧,洪慧丰. 金刚烷胺致下肢水肿、幻觉及睡眠、排尿障碍1例[J]. 中国冶金工业医学杂志,2016,33(4):375. [6] 上海勃林格殷格翰药业有限公司. 盐酸普拉克索(森福罗)药品说明书[S]. 2011. [7] Zavala J A, Munhoz R P, Teive H A .Pramipexole-related chronic lower limb oedema in a patient with Parkinson's disease[J]. Journal of Clinical Neuroscience, 2012, 19(9):1298-1299. [8] Biglan K M, Holloway R G, Mcdermott M P, et al.Risk factors for somnolence, edema, and hallucinations in early Parkinson disease[J]. Neurology, 2007, 69(2):187-195. [9] Tan E K, Ondo W .Clinical Characteristics of Pramipexole-Induced Peripheral Edema[J]. Archives of Neurology, 2000, 57(5):729. [10] 范景辉,李海燕,周扬. 1例帕金森伴异动症患者口服普拉克索致双下肢水肿的病例分析[J]. 继续医学教育,2015,29(7):114-115. [11] Cicero C E, Nicoletti A, Mostile G, et al.A case of severe leg oedema in a patient with Parkinson's disease treated with pramipexole[J]. Postgraduate Medical Journal, 2016, 92(1090):484-484. [12] Kleiner-Fisman G, Fisman D N .Risk Factors for the Development of Pedal Edema in Patients Using Pramipexole[J]. Archives of Neurology, 2007, 64(6):820-824. |
| [1] | LI Xinying, BAO Lei, LI Shuran, ZHAO Ronghua, SUN Jing, XIE Dan, BAO Yanyan, GUO Shanshan, CUI Xiaolan, GENG Zihan. Effect of Shufeng Jiedu Capsules on the Production of Specific Antibodies against Influenza A H1N1 Virus and the Mechanisms [J]. Chinese Journal of Pharmacovigilance, 2025, 22(8): 841-850. |
| [2] | WANG Xinwei, PENG Yifeng, SUN Jing, JI Zuen, BAO Lei, LUO Henglei, GENG Zihan, ZHANG Hujuan, LI Shuran, ZHANG Jingsheng, GUO Shanshan, CUI Xiaolan, ZHAO Ronghua. Effect of Yiye Anti-Influenza Capsules on Pneumonia Induced by Human Coronavirus 229E Infection in Mice [J]. Chinese Journal of Pharmacovigilance, 2025, 22(8): 851-855. |
| [3] | XIE Rui, SUN Qiyue, LI Yanying, ZHANG Jingsheng, ZHAO Ronghua, GUO Shanshan, GENG Zihan, BAO Lei, GAO Shuangrong, CUI Xiaolan, XIE Dan, SUN Jing. Impacts of Shuangshenling Granules on a Cadmium-Induced Chronic Renal Failure Model of Mice [J]. Chinese Journal of Pharmacovigilance, 2025, 22(8): 856-862. |
| [4] | CHEN Siying, DING Xueli, LIU Shujia, ZHANG Xiaomeng, ZHANG Bing, LIN Zhijian. Modeling for Prediction of Cardiotoxicity of Chinese Herbal Medicines [J]. Chinese Journal of Pharmacovigilance, 2025, 22(8): 869-875. |
| [5] | CAI Haili, ZHANG Xiaomeng, LIU Yadi, CHEN Lijuan, WANG Yu, ZHANG Bing. Preventive Strategies for Anthracycline-Induced Cardiotoxicity Using Traditional Chinese Medicine via Ferroptosis Regulation [J]. Chinese Journal of Pharmacovigilance, 2025, 22(8): 876-882. |
| [6] | ZHENG Haiyun, WANG Zhigang, WU Hongwei, WANG Shaonan, WANG Bin. Identification of in vitro and in vivo Chemical Constituents of Buxin Anmian Decoction Based on UPLC-Q Exactive Orbitrap HRMS [J]. Chinese Journal of Pharmacovigilance, 2025, 22(8): 883-888. |
| [7] | SUN Ya, WANG Xu, SUN Zhi, ZHOU Yubing. Dose Analysis of Linezolid in Severe Patients with Sepsis Complicated with Acute Kidney Injury [J]. Chinese Journal of Pharmacovigilance, 2025, 22(8): 889-895. |
| [8] | SHI Qi, WANG Jianxin, WANG Guijie, LU Yueyang, ZHU Jiaxu, GAO Rui. Adjuvant Treatment of Acute Exacerbation of Chronic Obstructive Pulmonary Disease with Qingqi Huatan Pills: a Systematic Review [J]. Chinese Journal of Pharmacovigilance, 2025, 22(8): 914-919. |
| [9] | YING Jie, XU Xiaolong, LI Bo, LIU Tengwen, LIU Qingquan. Clinical Applications of Jinhua Qinggan Granules in the Treatment of Mild Influenza: a Meta-Analysis [J]. Chinese Journal of Pharmacovigilance, 2025, 22(8): 920-923. |
| [10] | KE Xiuqin, HAI Xuewu. 433 Cases of Adverse Drug Reactions Induced by Calcium Dobesilate Capsules [J]. Chinese Journal of Pharmacovigilance, 2025, 22(8): 924-927. |
| [11] | LIANG Jie. 172 Cases of Adverse Drug Reactions Induced by Antineoplastic Drugs [J]. Chinese Journal of Pharmacovigilance, 2025, 22(8): 928-932. |
| [12] | LIU Jiang, CHEN Jie, QIU Sihong, LI Na, ZHOU Ying, CHEN Yonggang, LUO Ji. Analysis of Adverse Drug Event Induced by Omacycline and Moxifloxacin Based on FAERS Databse [J]. Chinese Journal of Pharmacovigilance, 2025, 22(8): 933-936. |
| [13] | ZHAO Mudan, ZHU Minghui, ZHANG Huan, ZHAO Yuanyang, QIN Jing. Pharmaceutical Care of a Case of Diabetic Foot Infection Caused by Proteus penneri [J]. Chinese Journal of Pharmacovigilance, 2025, 22(8): 937-940. |
| [14] | ZHOU Yujie, HUANG Xiaojing, CHEN Mingyue, DU Pengqiang, WANG Aifeng. Two Cases of Severe Thrombocytopenia Caused by Cefoperazone Sulbactam Sodium [J]. Chinese Journal of Pharmacovigilance, 2025, 22(8): 941-943. |
| [15] | CHEN Huabao, LIU Wei, JIANG Ting, ZHENG Lingli, LI Jing. One Case of Acute Withdrawal Syndrome Caused by Naloxone [J]. Chinese Journal of Pharmacovigilance, 2025, 22(8): 944-946. |
| Viewed | ||||||
|
Full text |
|
|||||
|
Abstract |
|
|||||
